Hypothesis

Modern lifestyles produce chronic mTORC1 activation that decouples nutrient signaling from the circadian clock, leading to a flattened oscillation of anabolic and catabolic programs. We hypothesize that restoring circadian‑gated mTORC1 pulsatility—by aligning brief nutrient‑driven mTOR spikes to the early active phase and allowing trough expression during the rest phase—will preserve the beneficial “civilization” functions of mTOR (protein synthesis, tissue specialization) while reinstating the “survival” programs (autophagy, stress resistance) that are lost under constant activation. This dual‑mode approach should improve healthspan metrics more effectively than either chronic mTOR inhibition or uncontrolled activation.

Mechanistic Rationale

mTORC1 activity directly phosphorylates core clock components such as BMAL1 and S6K1, influencing their stability and transcriptional output ([2]). When mTORC1 remains constitutively active, BMAL1 undergoes hyper‑phosphorylation, promoting its proteasomal degradation and dampening circadian amplitude ([3]). Conversely, pulsatile mTORC1 activity generates timed windows of phosphorylation that support BMAL1 cycling without triggering degradation, thereby sustaining robust circadian rhythms of metabolic genes. These rhythms, in turn, gate lysosomal biogenesis and autophagy gene expression (e.g., LC3, ATG5) to the resting phase, ensuring catabolic repair occurs when anabolic demand is low.

Thus, the civilization‑versus‑survival dial is not merely a static switch but a temporally encoded signal: peaks of mTORC1 drive tissue‑specific biosynthesis (the civilization mode) while troughs permit AMPK‑ULK1‑dependent autophagy and NAD⁺‑dependent sirtuin activation (the survival mode). Modern constant feeding and light exposure erase this temporal encoding, converting the dial into a stuck‑on position that favors growth at the expense of repair.

Testable Predictions

1. In vivo timing experiment – Adult C57BL/6J mice will receive an isocaloric leucine‑rich bolus either at zeitgeber time (ZT) 4 (early active phase) or ZT16 (early rest phase) daily for 12 weeks. Control groups receive constant leucine infusion via osmotic pump or vehicle. We predict that the ZT4 leucine pulse group will show:

   • Higher skeletal muscle protein synthesis rates (measured by SUnSET assay) compared with constant leucine.
   • Enhanced nocturnal autophagy flux in liver and brain (LC3‑II/I ratio increase, p62 degradation) relative to both constant leucine and rapamycin‑treated mice.
   • Improved circadian amplitude of core clock genes (Bmal1, Per2) in liver tissue (qPCR) and better glucose tolerance.
   • Extended median lifespan relative to constant leucine and comparable to intermittent fasting, but superior to chronic rapamycin due to preserved anabolic capacity.

2. Pharmacological test – Administer a short‑acting mTORC1 activator (e.g., MHY1485) coupled with a circadian‑controlled release formulation that peaks at ZT4, versus a long‑acting rapamycin formulation. We predict that the pulsatile activator will maintain mTORC1‑S6K signaling amplitude (phospho‑S6 Western blot) while restoring phospho‑BMAL1 cycling, whereas chronic rapamycin will blunt both mTORC1 and BMAL1 rhythms.

3. Human translational pilot – Participants undergoing a 6‑week time‑restricted eating protocol (10‑hour eating window ending at 18:00) will receive a protein‑rich breakfast within the first two hours of the window. Compared with an isocaloric protein spread across the day, the breakfast‑focused group will exhibit greater post‑prandial mTORC1 activity in peripheral blood mononuclear cells (p‑S6 flow cytometry) and higher nocturnal autophagic markers (circulating LC3‑II) alongside improved HOMA‑IR and subjective energy levels.

Falsifiability

If the ZT4 leucine pulse fails to increase muscle protein synthesis relative to constant leucine, or does not enhance nocturnal autophagy flux or circadian amplitude, the hypothesis that timed mTORC1 activation preserves both civilization and survival modes would be falsified. Likewise, if chronic rapamycin yields equal or better healthspan outcomes than the pulsatile activation regimen, the claim that preserving mTOR pulsatility is superior would be unsupported.

By linking mTOR’s anabolic signaling to circadian timing, this hypothesis reframes longevity interventions not as blanket suppression but as the restoration of a temporally encoded growth‑repair cycle that aligns cellular behavior with environmental cycles, thereby allowing organisms to retain the benefits of civilization without sacrificing the survival programs essential for long‑term maintenance.